Urology
Volume 68, Issue 6 , Pages 1268-1274 , December 2006

Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy)

  • Ashutosh Tewari

      Affiliations

    • Department of Urology, New York-Presbyterian Hospital, Cornell University Weill Medical College, New York, New York
    • Corresponding Author InformationReprint requests: Ashutosh Tewari, M.D., M.Ch., Department of Urology, New York-Presbyterian Hospital–Weill Cornell Medical Center, 525 East 68th Street, Starr 900, New York, NY 10021
    • ,
  • Jay D. Raman

      Affiliations

    • Department of Urology, New York-Presbyterian Hospital, Cornell University Weill Medical College, New York, New York
    • ,
  • Peter Chang

      Affiliations

    • Department of Urology, New York-Presbyterian Hospital, Cornell University Weill Medical College, New York, New York
    • ,
  • Sandhya Rao

      Affiliations

    • Department of Urology, New York-Presbyterian Hospital, Cornell University Weill Medical College, New York, New York
    • ,
  • George Divine

      Affiliations

    • Department of Radiation Oncology, Vattikuti Urology Institute, Josephine Ford Cancer Center, Henry Ford Health System, Detroit, Michigan
    • ,
  • Mani Menon

      Affiliations

    • Department of Radiation Oncology, Vattikuti Urology Institute, Josephine Ford Cancer Center, Henry Ford Health System, Detroit, Michigan

Received 3 January 2006 ,Accepted 11 August 2006.

References 

  1. Catalona WJ. Management of cancer of the prostate. N Engl J Med. 1994;331:996–1004
  2. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA. 1999;281:1598–1604
  3. Menon M, Parulkar BG, Baker S. Should we treat localized prostate cancer? (An opinion). Urology. 1995;46:607–616
  4. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347:781–789
  5. Bill-Axelson A, Holmberg L, Ruutu M, et al. Scandinavian Prostate Cancer Group Study No 4: radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977–1984
  6. Walsh PC, Brooks JD. The Swedish prostate cancer paradox. JAMA. 1997;277:497–498
  7. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 1997;349:906–910
  8. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878–1886
  9. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887–1892
  10. Albertsen PC, Hanley JA, Gleason DF, et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280:975–980
  11. Fowler JE, Terrell FL, Renfroe DL. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol. 1996;156:1714–1718
  12. Calle EE, Terrell DD. Utility of the National Death Index for ascertainment of mortality among cancer prevention study II participants. Am J Epidemiol. 1993;137:235–241
  13. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions—standardizing data on outcomes. N Engl J Med. 1998;339:380–386
  14. Tewari A, Issa M, El-Galley R, et al. Genetic adaptive neural network to predict biochemical failure after radical prostatectomy: a multi-institutional study. Mol Urol. 2001;5:163–169
  15. Pound CR, Partin AW, Epstein JI, et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am. 1997;24:395–406
  16. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330:242–248
  17. Djavan B, Kadesky K, Klopukh B, et al. Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens. Eur Urol. 1998;33:261–270
  18. Fernandes ET, Sundaram CP, Long R, et al. Biopsy Gleason score: how does it correlate with the final pathological diagnosis in prostate cancer?. Br J Urol. 1997;79:615–617
  19. McLean M, Srigley J, Banerjee D, et al. Interobserver variation in prostate cancer Gleason scoring: are there implications for the design of clinical trials and treatment strategies?. Clin Oncol. 1997;9:222–225
  20. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597
  21. Dale W, Vijayakumar S, Lawlor EF, et al. Prostate cancer, race, and socioeconomic status: inadequate adjustment for social factors in assessing racial differences. Prostate. 1996;29:271–281
  22. Krieger N, Chen JT, Ebel G. Can we monitor socioeconomic inequalities in health? A survey of U.S. health departments’ data collection and reporting practices. Public Health Rep. 1997;112:481–491
  23. Krieger N, Williams DR, Moss NE. Measuring social class in US public health research: concepts, methodologies, and guidelines. Annu Rev Public Health. 1997;18:341–378
  24. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095–2101
  25. Johannson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291:2713–2719
  26. Donovan J, Hamdy F, Neal D, et al. Prostate Testing For Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7:1–88

PII: S0090-4295(06)01963-7

doi: 10.1016/j.urology.2006.08.1059

Urology
Volume 68, Issue 6 , Pages 1268-1274 , December 2006

Article Tools

* Image Usage & Resolution